Interventionelle und pharmakologische Behandlungsansätze für Fuchs-Endotheldystrophie

Translated title of the contribution: Medical and Semi-surgical Treatments for Fuchs Endothelial Corneal Dystrophy

Katrin Wacker, Keith Baratz, Michael P Fautsch, Sanjay V. Patel

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Unraveling the genetic mechanisms of Fuchs endothelial corneal dystrophy has opened new possibilities for future targeted medical therapy of the disease. Until these possibilities mature, regenerative semi-surgical approaches by cell injection or cell sheet transfer could help expand the donor pool, and possibly enable autologous transplantation. Descemet membrane stripping alone and acellular Descemet membrane transfer are more immediate surgical approaches that could be temporary treatments in some patients, though there is a lack of understanding of the factors that predict success for these procedures. Regardless of approach, clinical trials will be necessary, and clinicians should therefore try to standardize their methods of assessing disease severity and the outcomes of intervention.

Translated title of the contributionMedical and Semi-surgical Treatments for Fuchs Endothelial Corneal Dystrophy
Original languageGerman
JournalKlinische Monatsblatter fur Augenheilkunde
StateAccepted/In press - May 3 2018


  • cell injection
  • endothelial keratoplasty
  • Fuchs endothelial corneal dystrophy
  • ROCK inhibitor
  • TCF4 gene
  • trinucleotide repeat expansion

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Medical and Semi-surgical Treatments for Fuchs Endothelial Corneal Dystrophy'. Together they form a unique fingerprint.

Cite this